Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy

Gaipov A., Taubaldiyeva Z., Askarov M., Turebekov Z., Popova N.

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction and Aims: Diabetic nephropathy is one of the leading causes of ESRD worldwide. Recent pre-clinical studies have been showed promising tool to treatment of type 1 diabetes mellitus via regeneration of pancreatic beta-cells. Some experimental studies reported direct renoprotective action of mesenchymal stem cells without normalisation of hyperglycaemia.We aimed to study influence of autologous bone marrow-derived stem cells (BMDSCs) therapy in amelioration of kidney function type 1 diabetic nephropathy patients. Methods: This is a preliminary data of prospective cohort study which included 5 patients (2 male and 3 female) with type 1 diabetic nephropathy, who had completed 2 visits during 6 months. Autologous BMDSCs were prepared from each patient (from the posterior iliac crest of patients under local anaesthesia) and cultivated in DMEM medium and incubated at 37c for three days according to cell preparation protocol. All of the patients received autologous BMDSCs (up to 140x106 cells) via IV infusion according to study protocol every 6 months. Routine physical and laboratory data were obtained at each visit. Markers providing renal deterioration such as microalbuminuria, urinary type IV collagen, urinary neutrophil gelatinase-associated lipocalin (NGAL) and urinary transforming growth factor (TGF)-beta1 were also determined at each visit. Results: Descriptive analysis showed that mean age of patients were 23,2+/-4,08 years, duration of diabetes 117,6+/-63,7 months, maximal glucose level 12,6+/-1,69 mmol/L during one year follow-up time. Baseline (I visit) and control (II visit) laboratory data after autologous BMDSCs therapy is presented in Table 1. All of the parameters providing pancreatic endocrine function showed trend to improvement, but non significant except fasting glucose (p=0,035). In some cases, patients reduced dose of insulin and oral antidiabetic medications. Markers indicating renal deterioration also improved after single dose autologous BMDSCs therapy but not significantly except microalbuminuria (p=0,026). Conclusions: Autologous bone marrow-derived stem cells transplantation is a safe and may be beneficial in type 1 diabetes mellitus with nephropathy. Further studies with a large number of patients are needed to substantiate these observations. (Table Presented).
Original languageEnglish
Title of host publicationNephrology Dialysis Transplantation
Place of PublicationA. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan
PublisherOxford University Press
Pagesiii534
ISBN (Print)0931-0509
Publication statusPublished - 2015

Publication series

NameNephrology Dialysis Transplantation
Volume30

Fingerprint

Type 1 Diabetes Mellitus
Stem Cells
Bone Marrow
Kidney
Diabetic Nephropathies
Cell- and Tissue-Based Therapy
Transforming Growth Factor beta1
Glucose
Collagen Type IV
Insulin-Secreting Cells
Stem Cell Transplantation
Local Anesthesia
Mesenchymal Stromal Cells
Hypoglycemic Agents
Hyperglycemia
Chronic Kidney Failure
Regeneration
Fasting
Cohort Studies
Prospective Studies

Keywords

  • *bone marrow
  • *deterioration
  • *edetic acid
  • *insulin dependent diabetes mellitus
  • *kidney disease
  • *marker
  • *stem cell
  • antidiabetic agent
  • clinical study
  • cohort analysis
  • collagen
  • diabetes mellitus
  • diabetic nephropathy
  • diet restriction
  • drug therapy
  • end stage renal disease
  • endocrine function
  • experimental study
  • female
  • follow up
  • glucose
  • human
  • iliac crest
  • insulin
  • intravenous drug administration
  • kidney function
  • laboratory
  • local anesthesia
  • male
  • mesenchymal stem cell
  • microalbuminuria
  • neutrophil gelatinase associated lipocalin
  • parameters
  • patient
  • regeneration
  • single drug dose
  • therapy
  • transforming growth factor
  • transplantation

Cite this

A., G., Z., T., M., A., Z., T., & N., P. (2015). Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy. In Nephrology Dialysis Transplantation (pp. iii534). (Nephrology Dialysis Transplantation; Vol. 30). A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan: Oxford University Press.

Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy. / A., Gaipov; Z., Taubaldiyeva; M., Askarov; Z., Turebekov; N., Popova.

Nephrology Dialysis Transplantation. A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan : Oxford University Press, 2015. p. iii534 (Nephrology Dialysis Transplantation; Vol. 30).

Research output: Chapter in Book/Report/Conference proceedingChapter

A., G, Z., T, M., A, Z., T & N., P 2015, Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy. in Nephrology Dialysis Transplantation. Nephrology Dialysis Transplantation, vol. 30, Oxford University Press, A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan, pp. iii534.
A. G, Z. T, M. A, Z. T, N. P. Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy. In Nephrology Dialysis Transplantation. A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan: Oxford University Press. 2015. p. iii534. (Nephrology Dialysis Transplantation).
A., Gaipov ; Z., Taubaldiyeva ; M., Askarov ; Z., Turebekov ; N., Popova. / Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy. Nephrology Dialysis Transplantation. A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan : Oxford University Press, 2015. pp. iii534 (Nephrology Dialysis Transplantation).
@inbook{74312a49a3b0401ba46fd00400e06250,
title = "Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy",
abstract = "Introduction and Aims: Diabetic nephropathy is one of the leading causes of ESRD worldwide. Recent pre-clinical studies have been showed promising tool to treatment of type 1 diabetes mellitus via regeneration of pancreatic beta-cells. Some experimental studies reported direct renoprotective action of mesenchymal stem cells without normalisation of hyperglycaemia.We aimed to study influence of autologous bone marrow-derived stem cells (BMDSCs) therapy in amelioration of kidney function type 1 diabetic nephropathy patients. Methods: This is a preliminary data of prospective cohort study which included 5 patients (2 male and 3 female) with type 1 diabetic nephropathy, who had completed 2 visits during 6 months. Autologous BMDSCs were prepared from each patient (from the posterior iliac crest of patients under local anaesthesia) and cultivated in DMEM medium and incubated at 37c for three days according to cell preparation protocol. All of the patients received autologous BMDSCs (up to 140x106 cells) via IV infusion according to study protocol every 6 months. Routine physical and laboratory data were obtained at each visit. Markers providing renal deterioration such as microalbuminuria, urinary type IV collagen, urinary neutrophil gelatinase-associated lipocalin (NGAL) and urinary transforming growth factor (TGF)-beta1 were also determined at each visit. Results: Descriptive analysis showed that mean age of patients were 23,2+/-4,08 years, duration of diabetes 117,6+/-63,7 months, maximal glucose level 12,6+/-1,69 mmol/L during one year follow-up time. Baseline (I visit) and control (II visit) laboratory data after autologous BMDSCs therapy is presented in Table 1. All of the parameters providing pancreatic endocrine function showed trend to improvement, but non significant except fasting glucose (p=0,035). In some cases, patients reduced dose of insulin and oral antidiabetic medications. Markers indicating renal deterioration also improved after single dose autologous BMDSCs therapy but not significantly except microalbuminuria (p=0,026). Conclusions: Autologous bone marrow-derived stem cells transplantation is a safe and may be beneficial in type 1 diabetes mellitus with nephropathy. Further studies with a large number of patients are needed to substantiate these observations. (Table Presented).",
keywords = "*bone marrow, *deterioration, *edetic acid, *insulin dependent diabetes mellitus, *kidney disease, *marker, *stem cell, antidiabetic agent, clinical study, cohort analysis, collagen, diabetes mellitus, diabetic nephropathy, diet restriction, drug therapy, end stage renal disease, endocrine function, experimental study, female, follow up, glucose, human, iliac crest, insulin, intravenous drug administration, kidney function, laboratory, local anesthesia, male, mesenchymal stem cell, microalbuminuria, neutrophil gelatinase associated lipocalin, parameters, patient, regeneration, single drug dose, therapy, transforming growth factor, transplantation",
author = "Gaipov A. and Taubaldiyeva Z. and Askarov M. and Turebekov Z. and Popova N.",
year = "2015",
language = "English",
isbn = "0931-0509",
series = "Nephrology Dialysis Transplantation",
publisher = "Oxford University Press",
pages = "iii534",
booktitle = "Nephrology Dialysis Transplantation",
address = "United Kingdom",

}

TY - CHAP

T1 - Impact of autologous bone marrow-derived stem cells to markers of renal deterioration in type 1 diabetes mellitus with nephropathy

AU - A., Gaipov

AU - Z., Taubaldiyeva

AU - M., Askarov

AU - Z., Turebekov

AU - N., Popova

PY - 2015

Y1 - 2015

N2 - Introduction and Aims: Diabetic nephropathy is one of the leading causes of ESRD worldwide. Recent pre-clinical studies have been showed promising tool to treatment of type 1 diabetes mellitus via regeneration of pancreatic beta-cells. Some experimental studies reported direct renoprotective action of mesenchymal stem cells without normalisation of hyperglycaemia.We aimed to study influence of autologous bone marrow-derived stem cells (BMDSCs) therapy in amelioration of kidney function type 1 diabetic nephropathy patients. Methods: This is a preliminary data of prospective cohort study which included 5 patients (2 male and 3 female) with type 1 diabetic nephropathy, who had completed 2 visits during 6 months. Autologous BMDSCs were prepared from each patient (from the posterior iliac crest of patients under local anaesthesia) and cultivated in DMEM medium and incubated at 37c for three days according to cell preparation protocol. All of the patients received autologous BMDSCs (up to 140x106 cells) via IV infusion according to study protocol every 6 months. Routine physical and laboratory data were obtained at each visit. Markers providing renal deterioration such as microalbuminuria, urinary type IV collagen, urinary neutrophil gelatinase-associated lipocalin (NGAL) and urinary transforming growth factor (TGF)-beta1 were also determined at each visit. Results: Descriptive analysis showed that mean age of patients were 23,2+/-4,08 years, duration of diabetes 117,6+/-63,7 months, maximal glucose level 12,6+/-1,69 mmol/L during one year follow-up time. Baseline (I visit) and control (II visit) laboratory data after autologous BMDSCs therapy is presented in Table 1. All of the parameters providing pancreatic endocrine function showed trend to improvement, but non significant except fasting glucose (p=0,035). In some cases, patients reduced dose of insulin and oral antidiabetic medications. Markers indicating renal deterioration also improved after single dose autologous BMDSCs therapy but not significantly except microalbuminuria (p=0,026). Conclusions: Autologous bone marrow-derived stem cells transplantation is a safe and may be beneficial in type 1 diabetes mellitus with nephropathy. Further studies with a large number of patients are needed to substantiate these observations. (Table Presented).

AB - Introduction and Aims: Diabetic nephropathy is one of the leading causes of ESRD worldwide. Recent pre-clinical studies have been showed promising tool to treatment of type 1 diabetes mellitus via regeneration of pancreatic beta-cells. Some experimental studies reported direct renoprotective action of mesenchymal stem cells without normalisation of hyperglycaemia.We aimed to study influence of autologous bone marrow-derived stem cells (BMDSCs) therapy in amelioration of kidney function type 1 diabetic nephropathy patients. Methods: This is a preliminary data of prospective cohort study which included 5 patients (2 male and 3 female) with type 1 diabetic nephropathy, who had completed 2 visits during 6 months. Autologous BMDSCs were prepared from each patient (from the posterior iliac crest of patients under local anaesthesia) and cultivated in DMEM medium and incubated at 37c for three days according to cell preparation protocol. All of the patients received autologous BMDSCs (up to 140x106 cells) via IV infusion according to study protocol every 6 months. Routine physical and laboratory data were obtained at each visit. Markers providing renal deterioration such as microalbuminuria, urinary type IV collagen, urinary neutrophil gelatinase-associated lipocalin (NGAL) and urinary transforming growth factor (TGF)-beta1 were also determined at each visit. Results: Descriptive analysis showed that mean age of patients were 23,2+/-4,08 years, duration of diabetes 117,6+/-63,7 months, maximal glucose level 12,6+/-1,69 mmol/L during one year follow-up time. Baseline (I visit) and control (II visit) laboratory data after autologous BMDSCs therapy is presented in Table 1. All of the parameters providing pancreatic endocrine function showed trend to improvement, but non significant except fasting glucose (p=0,035). In some cases, patients reduced dose of insulin and oral antidiabetic medications. Markers indicating renal deterioration also improved after single dose autologous BMDSCs therapy but not significantly except microalbuminuria (p=0,026). Conclusions: Autologous bone marrow-derived stem cells transplantation is a safe and may be beneficial in type 1 diabetes mellitus with nephropathy. Further studies with a large number of patients are needed to substantiate these observations. (Table Presented).

KW - bone marrow

KW - deterioration

KW - edetic acid

KW - insulin dependent diabetes mellitus

KW - kidney disease

KW - marker

KW - stem cell

KW - antidiabetic agent

KW - clinical study

KW - cohort analysis

KW - collagen

KW - diabetes mellitus

KW - diabetic nephropathy

KW - diet restriction

KW - drug therapy

KW - end stage renal disease

KW - endocrine function

KW - experimental study

KW - female

KW - follow up

KW - glucose

KW - human

KW - iliac crest

KW - insulin

KW - intravenous drug administration

KW - kidney function

KW - laboratory

KW - local anesthesia

KW - male

KW - mesenchymal stem cell

KW - microalbuminuria

KW - neutrophil gelatinase associated lipocalin

KW - parameters

KW - patient

KW - regeneration

KW - single drug dose

KW - therapy

KW - transforming growth factor

KW - transplantation

UR - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&PAGE=reference&D=emed17&NEWS=N&AN=72207792

UR - http://www.mendeley.com/research/impact-autologous-bone-marrowderived-stem-cells-markers-renal-deterioration-type-1-diabetes-mellitus

M3 - Chapter

SN - 0931-0509

T3 - Nephrology Dialysis Transplantation

SP - iii534

BT - Nephrology Dialysis Transplantation

PB - Oxford University Press

CY - A. Gaipov, National Scientific Medical Research Center, Extracorporeal Hemocorrection, Asana, Kazakhstan

ER -